This Is MS Multiple Sclerosis Knowledge & Support Community

Hello friends! I have not communicated for a long time, but I have tried to be attentive in some other areas that seem concurrent and excite me. Maybe you already know it, but sill I would like to share all this with you In a tough end of the year, but with faith and hope in this exciting time that ...

GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC) Geneva, Switzerland, June 25, 2020 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on st...

Multiple sclerosis: Endogenous retrovirus HERV-W key to nerve tissue damage Neurology: Publication in PNAS 27 June 2019 – Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) affecting brain and spinal cord. In collaboration with colleagues from the USA and Canada, a...

Please take a look:


http://multiple-sclerosis-research.blog ... .html#more

Please take a look:
http://medday-pharma.com/news-and-event ... sclerosis/

The Black Swan we are waiting for?: http://www.geneuro.com/data/news/geneur ... -ms-en.pdf

Please take a look:
http://www.cambridge-news.co.uk/busines ... g-13129687

and this:
https://www.nature.com/nnano/journal/va ... 7.134.html

Unknown Soldiers: UVA Discovers Powerful Defenders of the Brain

Please take a look:

https://news.virginia.edu/content/unkno ... ders-brain

Inhibiting the Autoimmune Response to Treat Multiple Sclerosis

http://www.bioe.umd.edu/news/news_story.php?id=9958

Full text:
http://www.cell.com/cell-reports/fulltext/S2211-1247(16%2931097-X

HI SEEVA!, one step closer... "Just keep swimming", as Doris says. here some aditional info (not especific for ms but very interesing too): Top 10 Google Stem Cell News Stories: Perspectives http://www.ipscell.com/2016/09/top-10-google-stem-cell-news-stories-perspectives/ source: The Niche...

Friday, September 02, 2016 MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal Paris, France, 2 September 2016 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces the online publication of results from the previou...

Editorial by Deborah Sweet on encouraging readers to take action on stem cell clinics.
(Cell Stem Cell)

http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16%2930209-0

Paul Alster from The Jerusalem Post wrote this encouraging report.

http://www.jpost.com/Jerusalem-Report/O ... ine-459639

Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

http://media.biogen.com/press-release/i ... anti-lingo

Another interesting point of view in this blog:

http://multiple-sclerosis-research.blog ... mment-form